Asif Rizwan1, Xiaohui Ni1, Rachael O'Connor2, Samuel Singer2, Sean Carlin3, Jason Koutcher1, Kristen L. Zakian1
1Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 2Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; 3Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
The lack of effective chemotherapy in de-differentiated liposarcoma leaves non-surgical candidates with few options. A non-invasive marker reflecting the effect of drugs could be quite valuable in pre-clinical drug evaluations. Furthermore, in the clinic, an early marker of response/non-response could permit the physician to discontinue ineffective treatment. Lactate, an end-product of glycolysis has the potential to be a biomarker of prognosis and treatment effect. The goal of the current study was to assess the change in lactate levels in a human DDLS tumor xenograft implanted in mice in response to chemotherapy.